{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:14:12Z","timestamp":1777857252495,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T00:00:00Z","timestamp":1550880000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2019,2,23]]},"abstract":"<jats:p>Nusinersen is the first disease-modifying therapy approved for the treatment of spinal muscular atrophy (SMA), a rare genetic disorder characterized by severe progressive muscular atrophy and weakness. An expanded access program (EAP) provides investigational treatment to patients without other treatment options. An EAP providing nusinersen treatment to individuals with the most severe form of SMA, infantile-onset SMA (consistent with SMA Type I), has enrolled over 800 participants as of September 2018, making it one of the largest in rare disease history. The successes, challenges experienced and opportunities for future consideration during the implementation of the nusinersen EAP are discussed.<\/jats:p>","DOI":"10.3233\/jnd-190387","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T17:10:40Z","timestamp":1558458640000},"page":"227-231","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges"],"prefix":"10.1177","volume":"6","author":[{"given":"Jonathan","family":"Yong","sequence":"first","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Moffett","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Lucas","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33474"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60921-6"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2008.01201.x"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1159\/000275492"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.04.009"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-37101-8.00139-9"},{"issue":"3","key":"ref007","first-page":"743","volume":"62","author":"Darras BT.","year":"2015","journal-title":"Spinal muscular atrophies"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1941310"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"ref012","author":"Swoboda KJ","year":"2018","journal-title":"World Muscle Society 23rd International Congress"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0711-7"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1177\/2168479017694850"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1177\/2168479015578154"},{"key":"ref016","unstructured":"ClinicalTrials.gov. Expanded access program (EAP) for nusinersen in participants with infantile-onset (consistent with Type 1) spinal muscular atrophy (SMA)\n                      . [Internet]: NIH U.S. National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02865109"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180315"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317412"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.05.010"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006281"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.006"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-190387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-190387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-190387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:53:39Z","timestamp":1777506819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-190387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,23]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,23]]}},"alternative-id":["10.3233\/JND-190387"],"URL":"https:\/\/doi.org\/10.3233\/jnd-190387","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,23]]}}}